STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

🇺🇸 STAT News Health (US) —
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics

AI Summary

AstraZeneca is investing $2 billion in Summit Therapeutics as the companies collaborate on testing ivonescimab with AstraZeneca antibody-drug conjugates. The partnership will assess the combination of the PD-1/VEGF bispecific drug with the company’s cancer therapies.

AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

Markets Deals Health AstraZeneca Summit Therapeutics investment ivonescimab cancer treatment drug combination clinical testing

Read original source →